213 related articles for article (PubMed ID: 32097656)
1. The protective role of DPP4 inhibitors in atherosclerosis.
Liu H; Guo L; Xing J; Li P; Sang H; Hu X; Du Y; Zhao L; Song R; Gu H
Eur J Pharmacol; 2020 May; 875():173037. PubMed ID: 32097656
[TBL] [Abstract][Full Text] [Related]
2. Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging.
Cao F; Wu K; Zhu YZ; Bao ZW
Front Endocrinol (Lausanne); 2021; 12():731273. PubMed ID: 34489872
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
Silva Júnior WS; Godoy-Matos AF; Kraemer-Aguiar LG
Biomed Res Int; 2015; 2015():816164. PubMed ID: 26146634
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway.
Chen Z; Yu J; Fu M; Dong R; Yang Y; Luo J; Hu S; Li W; Xu X; Tu L
Biochem Pharmacol; 2020 Jul; 177():113951. PubMed ID: 32251672
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
Mulvihill EE
Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors.
Matteucci E; Giampietro O
Curr Med Chem; 2015; 22(13):1573-81. PubMed ID: 25723507
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.
Mulvihill EE; Drucker DJ
Endocr Rev; 2014 Dec; 35(6):992-1019. PubMed ID: 25216328
[TBL] [Abstract][Full Text] [Related]
8. Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of subclinical atherosclerosis in Chinese patients with newly diagnosed type 2 diabetes: a cross-sectional study.
Zheng TP; Liu YH; Yang LX; Qin SH; Liu HB
Atherosclerosis; 2015 Oct; 242(2):580-8. PubMed ID: 26318108
[TBL] [Abstract][Full Text] [Related]
9. Effects of dipeptidyl peptidase 4 inhibition on the endothelial control of the vascular tone.
Ribeiro-Silva JC; Marques VB; Dos Santos L
Am J Physiol Cell Physiol; 2023 Oct; 325(4):C972-C980. PubMed ID: 37642237
[TBL] [Abstract][Full Text] [Related]
10. Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease.
Remm F; Franz WM; Brenner C
Eur Heart J Cardiovasc Pharmacother; 2016 Jul; 2(3):185-93. PubMed ID: 27533760
[TBL] [Abstract][Full Text] [Related]
11. The regulatory role of DPP4 in atherosclerotic disease.
Duan L; Rao X; Xia C; Rajagopalan S; Zhong J
Cardiovasc Diabetol; 2017 Jun; 16(1):76. PubMed ID: 28619058
[TBL] [Abstract][Full Text] [Related]
12. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
Zhong J; Rao X; Rajagopalan S
Atherosclerosis; 2013 Feb; 226(2):305-14. PubMed ID: 23083681
[TBL] [Abstract][Full Text] [Related]
13. Glucagon like Peptide-1 and atherosclerosis.
Mita T; Watada H
Cardiovasc Hematol Agents Med Chem; 2012 Dec; 10(4):309-18. PubMed ID: 22827292
[TBL] [Abstract][Full Text] [Related]
14. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
Zhong J; Maiseyeu A; Davis SN; Rajagopalan S
Circ Res; 2015 Apr; 116(8):1491-504. PubMed ID: 25858071
[TBL] [Abstract][Full Text] [Related]
15. Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus.
Barchetta I; Ciccarelli G; Barone E; Cimini FA; Ceccarelli V; Bertoccini L; Sentinelli F; Tramutola A; Del Ben M; Angelico F; Baroni MG; Lenzi A; Cavallo MG
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1087-1094. PubMed ID: 31431395
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation.
Lee CS; Kim YG; Cho HJ; Park J; Jeong H; Lee SE; Lee SP; Kang HJ; Kim HS
Sci Rep; 2016 Jul; 6():29393. PubMed ID: 27381080
[TBL] [Abstract][Full Text] [Related]
17. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications.
Avogaro A; Fadini GP
Diabetes Care; 2014 Oct; 37(10):2884-94. PubMed ID: 25249673
[TBL] [Abstract][Full Text] [Related]
18. Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM).
Mora-Rodríguez JM; Sánchez BG; Bort A; Díaz-Yuste A; Ballester-González R; Arrieta F; Sebastián-Martín A; Díaz-Laviada I
Life Sci; 2024 Jan; 336():122292. PubMed ID: 38030058
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies.
Zhong J; Kankanala S; Rajagopalan S
Curr Opin Lipidol; 2016 Oct; 27(5):484-92. PubMed ID: 27472408
[TBL] [Abstract][Full Text] [Related]
20. The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence.
Pala L; Rotella CM
J Diabetes Res; 2013; 2013():590456. PubMed ID: 23853775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
